• PFOS Induces Ferroptosis and ER Stress in Human Kidney Cells

  2026-04-29

  This study provides new mechanistic insights into how perfluorooctane sulfonate (PFOS) causes injury in human proximal tubular epithelial (HK-2) cells via ferroptosis and endoplasmic reticulum (ER) stress pathways. These findings clarify molecular events underlying PFOS nephrotoxicity, informing future research on environmental toxicants and kidney disease.

• Puromycin dihydrochloride: Technical Guidance for Cell Selec

  2026-04-28

  Puromycin dihydrochloride is used for precise selection and maintenance of eukaryotic and prokaryotic cell lines expressing the pac gene, and for probing translation and ribosome function. Its use is optimal in workflows requiring stringent protein synthesis inhibition or selection marker application, but must be carefully titrated to each cell type to avoid nonspecific cytotoxicity.

• Decoding Protein Dynamics: The Science of Triple Color Prest

  2026-04-28

  Explore how the Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) transforms SDS-PAGE and Western blot workflows. This article delves into its scientific design, advanced compatibility, and unique benefits for phosphoprotein and fluorescent imaging assays.

• Neurotensin: Precision Neurotensin Receptor 1 Activator Work

  2026-04-27

  Neurotensin (CAS 39379-15-2) empowers advanced investigations into GPCR trafficking and miRNA regulation, overcoming workflow bottlenecks tied to spectral interference and reproducibility. APExBIO’s high-purity peptide delivers reliable, interference-resistant results in both fluorescence-based and conventional assays, making it indispensable for cutting-edge gastrointestinal physiology research.

• Raising the Bar: Cap 1 Luciferase mRNA for Translational Sci

  2026-04-27

  Explore how EZ Cap™ Firefly Luciferase mRNA, featuring Cap 1 structure and an optimized poly(A) tail, is driving a paradigm shift in translational assay design. This thought-leadership article blends mechanistic insights with real-world workflow guidance, benchmarking against current literature on mRNA stability, delivery, and in vivo efficacy. Discover how APExBIO’s innovation helps researchers overcome bioluminescent assay challenges, bridge in vitro and in vivo gaps, and set new standards in molecular biology.

• HBTU in Advanced Peptide Synthesis: Workflow, Troubleshootin

  2026-04-26

  HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) delivers reproducible, racemization-resistant peptide bond formation for demanding synthetic applications. Learn how this APExBIO reagent empowers high-yield, selective workflows and enables next-generation peptide therapeutics, as exemplified by dual enzyme-responsive cancer-selective peptide assemblies.

• Gamithromycin (BA1074): Mechanism, Evidence, and Veterinary

  2026-04-25

  Gamithromycin (ML-1709460) is a semi-synthetic macrolide antibiotic with documented broad-spectrum efficacy against respiratory pathogens in veterinary species. Its mechanism—targeting bacterial protein synthesis via the 50S ribosomal subunit—enables potent, concentration-dependent activity. Dose optimization is driven by PK/PD indices, notably AUC24h/MIC, supporting its application in the treatment of bovine respiratory disease and Glässer’s disease in pigs.

• Cy5 Goat Anti-Mouse IgG (H+L) Antibody: Signal Amplification

  2026-04-24

  Uncover new scientific insights into the Cy5 Goat Anti-Mouse IgG (H+L) Antibody, a Cy5-conjugated secondary antibody from APExBIO. This article reveals how advanced signal amplification strategies transform mouse IgG detection across immunoassays, with unique practical guidance and evidence-backed protocol insights.

• SFTSV NSs Activate NLRP1/CARD8 Inflammasomes by Disrupting D

  2026-04-24

  Liu et al. (2025) report a novel mechanism by which the SFTSV non-structural protein (NSs) directly activates NLRP1 and CARD8 inflammasomes, bypassing canonical triggers by destabilizing the inhibitory DPP8/9 ternary complex. This discovery clarifies pathogen sensing in innate immunity and suggests new research routes for targeting inflammasome regulation in infection and cancer.

• Translational Leverage: EdU Imaging Kits (Cy3) in S-Phase Re

  2026-04-23

  This article delivers a strategic, evidence-backed perspective on using EdU Imaging Kits (Cy3) to advance translational cell proliferation research. Integrating mechanistic rationale, benchmarking, and direct insights from recent kidney development studies, it provides actionable guidance for maximizing experimental fidelity, with special focus on S-phase DNA synthesis detection and translational bottlenecks. Content is differentiated by bridging core mechanistic advances with protocol-level recommendations and real-world strategic implications.

• N6-Methyl-dATP: Precision Epigenetics for DNA Replication Fi

  2026-04-23

  N6-Methyl-dATP empowers molecular biologists to dissect DNA polymerase selectivity and methylation-driven regulation with unprecedented clarity. Its application streamlines workflows for genomic stability studies and epigenetic modulation, enabling robust troubleshooting and innovation in advanced cancer and antiviral research.

• Ciprofloxacin Potentiates RSL3-Induced Ferroptosis via Mitoc

  2026-04-22

  This study reveals that ciprofloxacin, beyond its antibiotic activity, enhances RSL3-induced ferroptosis in cancer cells by promoting mitochondrial Zn2+ accumulation through the STING1–CAV2 signaling pathway. The mechanistic insights into zinc homeostasis and cell death modulation establish a framework for targeted ferroptosis-based cancer therapies.

• Cisplatin (CDDP): Mechanism, Pyroptosis, and Next-Gen Cancer

  2026-04-22

  Explore how Cisplatin (CDDP) not only induces apoptosis but also triggers pyroptosis in cancer cells, revealing novel opportunities for apoptosis assay design and chemoresistance research. This article uniquely integrates recent pyroptosis insights with advanced experimental strategies, positioning APExBIO's Cisplatin as an indispensable tool in modern cancer research.

• Nintedanib (BIBF 1120): Precision Use in Cancer Research Wor

  2026-04-21

  Nintedanib (BIBF 1120) stands out as a robust triple angiokinase inhibitor, enabling targeted angiogenesis inhibition in cancer and fibrosis models. This article translates advanced experimental protocols, troubleshooting strategies, and key findings from recent glioma research into actionable guidance for laboratories seeking reproducibility and mechanistic clarity.

• Novel Methylene Ziprasidone Dimer Impurity Identified in Zip

  2026-04-21

  A recent study identified and structurally characterized a previously unknown methylene ziprasidone dimer (MZD) impurity in manufacturing batches of ziprasidone hydrochloride. This finding highlights the importance of advanced impurity profiling for maintaining the safety and efficacy of atypical antipsychotic agents, with practical implications for both pharmaceutical quality control and neuroscience research.

407 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page